Scandion Oncology has been informed that the European Patent Office (EPO) intends to grant the Composition-of-Matter patent for Scandion?s lead compound SCO-101. This decision follows the positive opinion issued by the EPO in January 2023. If granted, the new patent will cover solid crystal forms of SCO-101, which includes the form of the compound that Scandion expects to be commercialized.

Expiring in 2042, the patent will extend the potential commercial exclusivity period for SCO-101. This could allow Scandion to expand the development of SCO-101 into new indications and drug combinations, potentially making a future treatment available to more patients. SCO-101 is currently being clinically developed as a combination treatment for metastatic colorectal cancer and pancreatic cancer.

Scandion believes that SCO-101 can revert cancer?s resistance to treatments like chemotherapy thereby making the treatments work better and longer. cancer drug resistance continues to constitute a huge unmet medical need. Following grant of the patent in Europe, Scandion expects to extend the patent to a number of countries outside Europe.